news archive

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

02.21.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02.05.2020

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

01.13.2020

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

01.10.2020

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People with High Frequency Basal Cell Carcinoma

01.08.2020

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

01.06.2020

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

12.19.2019

BridgeBio Pharma’s Origin Biosciences Enters Partnership with Medison To Commercialize BBP-870 In Israel for MoCD Type A

12.18.2019

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

12.16.2019

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

12.09.2019

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.05.2019

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A

12.03.2019

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

12.02.2019

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.27.2019

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

11.16.2019

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

11.07.2019

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

10.22.2019

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

10.17.2019

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

10.14.2019

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

09.24.2019

news archive

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BridgeBio disavows any obligation to update the information contained in such press releases after the date of their issuance.

back to news

icon icon